Ensartinib for advanced or metastatic non-small-cell lung cancer with <i>MET</i> exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial.

For osimertinib, the plasma clearance rate of mutated EGFR ctDNA has been shown to play a highly significant predictive role for both PFS and OS. 23 , 24 In our study, although the ORR was similar, mPFS displayed a trend toward prolongation in the baseline ctDNA-negative cohort compared to the ctDNA-positive cohort (3.7 m vs. 6.0 m).

also in 132,142 other papers